380899-24-1
基本信息
(S)-N-((1-(5-(4-氟苯基)-2-甲基噻唑-4-羰基)哌啶-2-基)甲基)苯并呋喃-4-甲酰胺
SB-649868
SB649868
SB 649868
SB-649868, CID25195495
N-[[(2S)-1-[[5-(4-Fluorophenyl)-2-methyl-4-thiazolyl]carbonyl]-2-piperidinyl]methyl]-4-benzofurancarboxamide
4-Benzofurancarboxamide, N-[[(2S)-1-[[5-(4-fluorophenyl)-2-methyl-4-thiazolyl]carbonyl]-2-piperidinyl]methyl]-
N-[[(2S)-1-[5-(4-FLUOROPHENYL)-2-METHYL-1,3-THIAZOLE-4-CARBONYL]PIPERIDIN-2-YL]METHYL]-1-BENZOFURAN-4-CARBOXAMIDE
物理化学性质
| 沸点 | 725.1±55.0 °C(Predicted) |
| 密度 | 1.305±0.06 g/cm3(Predicted) |
| 储存条件 | -20°C储存 |
| 溶解度 | DMF: 15mg/mL; DMF:PBS (pH 7.2) (1:20): 0.04mg/mL; DMSO: 10mg/mL; Ethanol: 0.3mg/mL |
| 酸度系数(pKa) | 14.54±0.46(Predicted) |
| 形态 | 结晶固体 |
| 颜色 | White to off-white |
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H315-H319-H335 |
| 防范说明 | P261-P305+P351+P338 |
SB-649868价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/11/08 | HY-10806 | SB-649868 SB-649868 | 380899-24-1 | 5mg | 1400元 |
| 2024/11/08 | HY-10806 | SB-649868 SB-649868 | 380899-24-1 | 10mg | 2400元 |
| 2024/11/08 | HY-10806 | SB-649868 SB-649868 | 380899-24-1 | 25mg | 5100元 |
常见问题列表
pKi: 9.4 (OX 1 ), 9.5 (OX 2 )
SB-649868 is identified as one the most in vitro potent dual OX 1 and OX 2 receptor antagonist known at that time (pK i =9.4 and 9.5 at the OX 1 and OX 2 receptor, respectively) . SB-649868 antagonizes orexin-A-induced inositol 1 phosphate (IP1) accumulation with the following pK B value (OX 1 =9.67; OX 2 =9.64). SB-649868 displaces the [ 3 H]ACT-078573 receptor binding with the following pKi values: OX 1 =9.27; OX 2 =8.91. Increasing concentrations of SB-649868 (0.3 nM-30 nM) induces a rightward shift of the orexin-A CRCs with a depression of the agonist efficacy suggesting a clear non-surmountable behavior. The calculated apparent pK b values are 9.67±0.03 and 9.64±0.07 for OX 1 and OX 2 .
Pharmacokinetic studies in the male CD rat, performed at 1 mg/kg, iv and 3 mg/kg, po, demonstrate an excellent pharmacokinetic profile for a hypnotic agent featuring moderate clearance in plasma (Cl p =24 mL/min/kg), short half-life of (<0.6 h) and a low volume of distribution (V ss =1.1 l/kg), coupled with excellent oral bioavailability (F=85%) and good exposure in plasma (C max =333 ng/mL). A brain to blood ratio (B/B) of 0.1:1 is observed 1 h after iv administration, a value in line with the expected partition between the two compartments based on the lower tissue binding observed in vitro in brain tissues (fraction unbound/brain=5.28%) with respect to plasma proteins (fraction unbound/plasma=1.34%). SB-649868, administered orally 3 h before OX-A injection at doses of 1, 3 and 10 mg/kg, causes a dose-dependent reduction of OX-A induced grooming as measured by total time spent grooming and number of grooming bouts (p <0.01 at 3 and 10 mg/kg po) . From dissociation kinetic studies using [ 3 H]ACT-078573, the calculated long half-life, (t 1/2 ) supports the non-surmountability profile of SB-649868 (t 1/2 =35.91 min) at OX 1 orexin receptor. The long or moderately long t 1/2 values for SB-649868 at OX 2 orexin receptor (t 1/2 =8.09 min).